Dinutuximab
| Evidence Level: L5 | Predicted Indications: 4 |
Table of Contents
- Dinutuximab
- Dinutuximab: From High-Risk Neuroblastoma to Vertebral Anomalies with Variable Endocrine and T-Cell Dysfunction
Dinutuximab: From High-Risk Neuroblastoma to Vertebral Anomalies with Variable Endocrine and T-Cell Dysfunction
One-Sentence Summary
Dinutuximab is an anti-GD2 monoclonal antibody, originally used to treat high-risk neuroblastoma. The TxGNN model predicts it may be effective for vertebral anomalies and variable endocrine and T-cell dysfunction, a rare developmental syndrome. There are currently 0 clinical trials and 0 publications supporting this prediction, so it rests on the model score alone.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | High-risk neuroblastoma |
| Predicted New Indication | Vertebral anomalies and variable endocrine and T-cell dysfunction |
| TxGNN Prediction Score | 99.42% |
| Evidence Level | L5 |
| US Market Status | ✓ Marketed |
| Number of NDAs | 1 (BLA125516) |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism of action data is not available in the database. Dinutuximab is a chimeric anti-GD2 antibody. It kills GD2-expressing tumor cells through antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC). Its efficacy in neuroblastoma is established.
The link to the predicted indication is weak. The predicted condition is a rare developmental syndrome, and no GD2-driven pathology is known for it. The 99.42% score (model rank 13,469) is a statistical association in the knowledge graph, not a demonstrated biological rationale. Without a target-related mechanism, the prediction should be treated as a hypothesis-generating signal only.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
US Market Information
| Authorization Number | Product Name | Dosage Form |
|---|---|---|
| BLA125516 | Unituxin (United Therapeutics Corporation) | Injection |
Cytotoxicity
| Item | Content |
|---|---|
| Cytotoxicity Classification | Immunotherapy (monoclonal antibody, anti-GD2); not a conventional cytotoxic agent |
| Myelosuppression Risk | Please refer to the package insert warnings and precautions |
| Emetogenicity Classification | Please refer to the package insert warnings and precautions |
| Monitoring Items | Please refer to the package insert warnings and precautions |
| Handling Protection | Please refer to the package insert warnings and precautions |
Safety Considerations
Please refer to the package insert for safety information.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction has no trials, no literature, and no plausible mechanistic link. It relies only on the model score, which is not enough to justify further investment.
To proceed, the following is needed:
- A mechanistic hypothesis showing GD2 involvement in this syndrome, such as GD2 expression in the affected tissues
- Preclinical or case-level evidence supporting any activity in this condition
- Package insert safety data (warnings and contraindications), which are needed for any safety screening
- Mechanism of action data from DrugBank
Related note: Within the same TxGNN output, ganglioneuroblastoma (rank 2, score 99.39%) has much stronger support. It has 7 registered trials, including a recruiting Phase 3 study (NCT06172296, n=478), a completed randomized Phase 2 trial (NCT01767194, n=73), and one published RCT (PMID 28549783). It is an Evidence Level L2 candidate with a “Proceed with Guardrails” recommendation. The trials and publication refer to neuroblastoma, not ganglioneuroblastoma specifically, so GD2 expression in the more differentiated histology should be verified. It is a better candidate for priority evaluation than the rank 1 prediction.
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.